To the Editor A recent study published by Wang et al1 evaluated POLE/POLD1 variants as potential biomarkers for immune checkpoint inhibitor (ICI) treatment outcomes in multiple cancer types using the cBioPortal database (https://www.cbioportal.org). The authors conclude that “mutations in all exons of these 2 genes should be integrated into predictive biomarker panels for ICI therapy.”1 However, this interpretation may be incorrect considering that not all POLE/POLD1 variants are oncogenic and therefore would not result in a high tumor mutation burden (TMB).
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Rousseau B, Vidal J, Diaz LA. Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes. JAMA Oncol. Published online March 05, 2020. doi:10.1001/jamaoncol.2020.0065
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: